JP2010511389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511389A5 JP2010511389A5 JP2009539524A JP2009539524A JP2010511389A5 JP 2010511389 A5 JP2010511389 A5 JP 2010511389A5 JP 2009539524 A JP2009539524 A JP 2009539524A JP 2009539524 A JP2009539524 A JP 2009539524A JP 2010511389 A5 JP2010511389 A5 JP 2010511389A5
- Authority
- JP
- Japan
- Prior art keywords
- circulating
- fibrosis
- subject
- disease
- fibrotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 45
- 238000000034 method Methods 0.000 claims 33
- 208000035475 disorder Diseases 0.000 claims 28
- 230000003176 fibrotic effect Effects 0.000 claims 28
- 210000002950 fibroblast Anatomy 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 17
- 206010016654 Fibrosis Diseases 0.000 claims 16
- 230000000893 fibroproliferative effect Effects 0.000 claims 16
- 230000004761 fibrosis Effects 0.000 claims 12
- 210000000630 fibrocyte Anatomy 0.000 claims 9
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 7
- 201000002793 renal fibrosis Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000033116 Asbestos intoxication Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 4
- 201000010001 Silicosis Diseases 0.000 claims 4
- 208000036866 Vitreoretinopathy Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 206010003441 asbestosis Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 229940044683 chemotherapy drug Drugs 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims 4
- 210000001508 eye Anatomy 0.000 claims 4
- 206010061989 glomerulosclerosis Diseases 0.000 claims 4
- 210000002216 heart Anatomy 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 claims 4
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000037390 scarring Effects 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 241000238366 Cephalopoda Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 210000000232 gallbladder Anatomy 0.000 claims 3
- 208000018578 heart valve disease Diseases 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 210000005166 vasculature Anatomy 0.000 claims 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 238000000684 flow cytometry Methods 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87201906P | 2006-11-30 | 2006-11-30 | |
| US60/872,019 | 2006-11-30 | ||
| PCT/US2007/086167 WO2008067559A2 (en) | 2006-11-30 | 2007-11-30 | Methods for treating and diagnosing fibrotic and fibroproliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010511389A JP2010511389A (ja) | 2010-04-15 |
| JP2010511389A5 true JP2010511389A5 (enExample) | 2011-01-20 |
| JP5296701B2 JP5296701B2 (ja) | 2013-09-25 |
Family
ID=39468768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539524A Active JP5296701B2 (ja) | 2006-11-30 | 2007-11-30 | 線維性疾患および線維増殖性疾患を処置および診断するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8114608B2 (enExample) |
| EP (1) | EP2100140B1 (enExample) |
| JP (1) | JP5296701B2 (enExample) |
| AU (1) | AU2007325029B2 (enExample) |
| WO (1) | WO2008067559A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008009437A2 (en) | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
| KR101589442B1 (ko) * | 2007-08-06 | 2016-02-01 | 녹손 파르마 아게 | 에스디에프-1 결합형 핵산 및 이의 용도 |
| CA2745027A1 (en) * | 2008-10-22 | 2010-04-29 | Allocure, Inc. | Methods of using sdf-1 (cxcl12) as a diagnostic and mesenchymal stem cell (multipotent stromal cell)-specific therapeutic biomarker for the treatment of kidney injury and other major organs |
| JP2012127879A (ja) * | 2010-12-16 | 2012-07-05 | Kanazawa Univ | 腎症の進行度の判定方法並びに線維化抑制剤。 |
| CN103376228B (zh) * | 2012-04-27 | 2016-02-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种检测或辅助检测放射性肺纤维化的试剂盒 |
| EP2972380A2 (en) * | 2013-03-14 | 2016-01-20 | Galapagos NV | Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis |
| JP6601707B2 (ja) * | 2015-02-15 | 2019-11-06 | 国立大学法人金沢大学 | 線維化判定方法 |
| JP7126668B2 (ja) * | 2017-08-09 | 2022-08-29 | 国立大学法人金沢大学 | 膠原病判定方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759036B1 (en) | 1997-03-28 | 2004-07-06 | The Picower Institute For Medical Research | Fibrocyte-base vaccine formulations |
| US8293479B2 (en) | 2002-05-02 | 2012-10-23 | Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center | Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies |
| JP4922560B2 (ja) * | 2002-12-23 | 2012-04-25 | ウイリアム、マーシュ、ライス、ユーニヴァーサティ | 線維細胞への分化の検出方法、線維症を抑制する組成物および方法 |
-
2007
- 2007-11-30 JP JP2009539524A patent/JP5296701B2/ja active Active
- 2007-11-30 US US12/516,912 patent/US8114608B2/en not_active Expired - Fee Related
- 2007-11-30 WO PCT/US2007/086167 patent/WO2008067559A2/en not_active Ceased
- 2007-11-30 EP EP20070865037 patent/EP2100140B1/en active Active
- 2007-11-30 AU AU2007325029A patent/AU2007325029B2/en not_active Ceased
-
2011
- 2011-12-15 US US13/327,025 patent/US8216796B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511389A5 (enExample) | ||
| Ryu et al. | Idiopathic pulmonary fibrosis: evolving concepts | |
| JP2021523103A (ja) | Ｉｌ−３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 | |
| Gooch et al. | Initial report on a phase I clinical trial: prevention and treatment of post-operative acute kidney injury with allogeneic mesenchymal stem cells in patients who require on-pump cardiac surgery | |
| Liu et al. | A complete heart regeneration model with inflammation as a key component | |
| Zhu et al. | Lund exhaust on hemodynamic parameters and inflammatory mediators in patients undergoing cardiac valve replacement under cardiopulmonary bypass | |
| Lu et al. | Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function | |
| JP2018162308A5 (enExample) | ||
| Tanaka et al. | Aortic valve replacement for aortic regurgitation with rare left ventricular non-compaction | |
| Szturmowicz et al. | Pulmonary hypertension in the course of diffuse parenchymal lung diseases—state of art and future considerations | |
| Channick et al. | Endothelin receptor antagonism: A new era in the treatment of pulmonary arterial hypertension | |
| Mahung et al. | 41 Peripheral Mononuclear Cell Expression of IL-10, IL-12, ARG1, & NOS2 Correlates with Outcomes After Burn | |
| Yu et al. | Effect of Epicardial Left Atrial Appendage Closure on the Early Prognosis of Patients with High-risk Heart Valve Disease Complicated with Atrial Fibrillation | |
| Bankir et al. | MO422: Strong Positive Association Between GFR and the Urine-To-Plasma Urea Concentration Ratio in Patients With Sickle Cell Disease. Possible Functional Meaning | |
| Tayyareci et al. | Intracoronary Autologous Bone Marrow− Derived Mononuclear Cell Transplantation Improves Coronary Collateral Vessel Formation and Recruitment Capacity in Patients With Ischemic Cardiomyopathy: A Combined Hemodynamic and Scintigraphic Approach | |
| Shevchenko et al. | Cardiac transplant rejection and non-invasive comon carotid artery wall functional indices | |
| Baernthaler et al. | Inhibiting Prostaglandin E2 Degradation Is Protective in a Mouse Model of Pulmonary Fibrosis | |
| Debicka-Dabrowska et al. | [PP. 36.04]: USEFULNESS OF SLOW BREATHING TRAINING IN CHRONIC HEART FAILURE. STUDY DESIGN AND INTERMEDIATE RESULTS | |
| Dovganych | LEFT ATRIAL REMODELLING IN HYPERTENSIVE PATIENTS: PP. 36.224 | |
| Omoto et al. | Aortic valve replacement in a patient with alpha-thalassemia | |
| Wein et al. | The cardiomyopathies | |
| Rebeko et al. | ELECTROPHYSIOLOGY DATA IN HYPERTENSIVE PATIENTS WITH AND WITHOUT HYPERTROPHY: PP. 36.226 | |
| Rodica et al. | Evaluation of Pulmonary Vasodilator Therapy with Endothelin-Receptor Antagonist in Eisenmenger Syndrome. | |
| JP2020533373A5 (enExample) | ||
| Peroš-Golubičić | Scleroderma and Lung |